Dr. Amikar Sehdev, MD

Dr. Sehdev practices at Ironwood Cancer & Research Centers in Glendale, Arizona.

Dr. Sehdev's NPI, 1588891667, was assigned on June 16, 2009. Dr. Sehdev holds Arizona license 58218.

Dr. Sehdev's primary practice is Ironwood Cancer & Research Centers, at 5810 W Beverly Ln, Glendale, AZ 85306 in Maricopa County. The practice phone is (480) 821-2838.

Dr. Sehdev's primary practice is Ironwood Cancer & Research Centers in Glendale, Arizona. Dr. Sehdev is also affiliated with Banner Thunderbird Medical Center. The medical group on file is Ironwood Cancer & Research Centers. Dmand AI also links Dr. Sehdev to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sehdev practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Sehdev's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Sehdev is licensed in Arizona.

CMS data shows 76,135 Medicare services from Dr. Sehdev across 31 procedure codes in 2024, for 549 Medicare patients. Medicare paid $999,289 for them.

CMS counts 549 Medicare patients who saw Dr. Sehdev in 2024. The largest group is 65 to 74, with 240 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sehdev's median patient age at 69, with 53% women.

In 2024, Dr. Sehdev wrote 932 Medicare Part D claims for 191 patients. 75% of them were for generic drugs. CMS names the drug for 738 of them, across 27 drugs with 11 or more claims each, at $1,134,446 in total drug cost. In 2023, CMS named 468 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Sehdev for performance year 2024. Dr. Sehdev accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sehdev as offering telehealth.

Dmand AI links 25 papers to Dr. Sehdev, published from 2012 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms and Adenocarcinoma. Dr. Sehdev has published most often in Discov Med. Dr. Sehdev's most frequent co-authors are Paul R. Helft, MD, Patrick J. Loehrer, MD and Blase N. Polite.

Dmand AI links Dr. Sehdev to 4 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Fatigue. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 652 general payments to Dr. Sehdev from 62 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 68% of the total. Eisai Inc. paid the most, $5,422.